<DOC>
	<DOCNO>NCT01476462</DOCNO>
	<brief_summary>Development second neoplasm ( SMN ) therapy childhood acute lymphoblastic leukemia ( ALL ) rare event generally associate poor prognosis . In international study analyze subtypes SMN relation initial leukemia characteristic treatment , subsequent overall survival .</brief_summary>
	<brief_title>Second Malignant Neoplasms After Childhood ALL Therapy</brief_title>
	<detailed_description>To explore epidemiology , potential risk factor survival rate second cancer occur first event childhood acute lymphoblastic leukemia involve study group collect anonymous data case diagnose within last decade form common database predefined variable comprise clinical , biological , cytogenetic characteristic ( myeloid neoplasia ) well outcome . Furthermore , register clinical , biological , cytogenetic characteristic acute lymphoblastic leukemia well type treatment give .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<criteria>Diagnosed childhood acute lymphoblastic leukemia Diagnosis second cancer December 31st 2007 Uncertainty second cancer emerge original leukemic clone</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Acute lymphoblastic leukemia</keyword>
	<keyword>Ponte-di-Legno consortium</keyword>
	<keyword>Second cancer</keyword>
	<keyword>Survival</keyword>
</DOC>